Kenvue (NYSE:KVUE) Now Covered by Jefferies Financial Group

Equities research analysts at Jefferies Financial Group assumed coverage on shares of Kenvue (NYSE:KVUE) in a research note issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a $27.00 price target on the stock. Jefferies Financial Group’s target price indicates a potential upside of 17.26% from the company’s current price.

A number of other research analysts have also issued reports on the stock. JPMorgan Chase & Co. upped their target price on shares of Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. UBS Group upped their price objective on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a report on Tuesday. Citigroup lowered their price objective on Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $22.10.

Kenvue Stock Down 0.4 %

Shares of NYSE KVUE opened at $23.03 on Tuesday. The firm’s 50-day moving average is $21.21 and its two-hundred day moving average is $20.03. The company has a market capitalization of $44.10 billion, a PE ratio of 29.52, a price-to-earnings-growth ratio of 2.92 and a beta of 1.40. Kenvue has a 12-month low of $17.67 and a 12-month high of $23.55. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE) last announced its earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The firm had revenue of $4 billion for the quarter, compared to analysts’ expectations of $3.93 billion. During the same quarter in the prior year, the firm earned $0.32 EPS. Kenvue’s quarterly revenue was down .3% on a year-over-year basis. Equities analysts anticipate that Kenvue will post 1.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Kenvue

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in Kenvue by 12.0% during the 1st quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company’s stock worth $3,579,294,000 after purchasing an additional 17,908,497 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Kenvue by 23.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company’s stock valued at $2,887,773,000 after buying an additional 25,238,112 shares during the period. Massachusetts Financial Services Co. MA lifted its position in Kenvue by 9.6% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 79,863,967 shares of the company’s stock worth $1,451,927,000 after acquiring an additional 7,023,047 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Kenvue by 6.7% in the 4th quarter. Wellington Management Group LLP now owns 76,501,956 shares of the company’s stock worth $1,647,087,000 after acquiring an additional 4,815,126 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Kenvue by 11.1% during the first quarter. JPMorgan Chase & Co. now owns 68,319,998 shares of the company’s stock valued at $1,466,147,000 after purchasing an additional 6,825,611 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.